


TBS Clinical News - February 2017

As 2017 started as a bright year for Medimaps, we are glad to share our recent exciting news.

In January, the annual meeting of the French Association for Osteoporosis, GRIO, was held. This 30th edition was marked by the presentation of the new guidelines for osteoporosis treatment from GRIO.

In this guideline update, **TBS** is integrated as a **prediction tool** useful to better define patients risk of fracture, whenever treatment recommendation is not obvious based on history of fracture and BMD.



The prediction tools at the disposal of physicians - FRAX®, TBS (and therefore FRAX adjusted for TBS) and bone markers - allow them to fine tune patients risk profile when cases require a deeper analysis, as highlighted in the following table by the "Physician Investigation" category:

Based on T-score (lowest site)	Severe Fractures (hip, spine, forearm, pelvis)	Non-severe fractures	No fracture and several risk factors for osteoporosis or fall
T > -1	Physician Investigation	No Treatment	No Treatment
T ≤ -1 and > -2	Treatment	Physician Investigation	No Treatment
T ≤ -2 and > -3	Treatment	Treatment	Physician Investigation
T ≤ -3	Treatment	Treatment	Treatment

Source: adapted from GRIO Guidelines for osteoporosis treatment Update 2016/2017, slidedeck available in French on GRIO website

As TBS was born in France, Medimaps is thrilled by the publication of new guidelines on TBS use by GRIO, as it will help TBS integration in the daily practice of all French users of TBS iNsight.

These new guidelines are in line with the **ISCD recommendations published in 2015**, and consistent with the **IOF and ESCEO** publications, that all highlight TBS as a new bone

parameter, independent and complementary to bone parameters currently accounting for in osteoporosis diagnosis and management.

In his Educative Session on TBS, Professor Cortet introduced **TBS added-value** in conditions where BMD does not reflect patients fracture risk increase, such as **Type 2 Diabetes**. Extensive literature showed that TBS is especially useful in **secondary osteoporosis** patient cases and can therefore help improve patient management.

Last but not least, we are glad to announce that our TBS Specialists will be waiting for you on **Booth#29** during the upcoming **WCO-IOF-ESCEO Congress** in the wonderful city of *Florence, from March 24th to 26th* to introduce TBS new features and some exciting clinical findings.

To know more, please review our available educational material and do not hesitate to activate your free trial:

[Compendium of TBS clinical case](#)

[Free 60-day & 250 scans trial](#)

[Or contact us](#)

In the coming months, TBS will be presented in the following events:

- ECR, Vienna, Austria, March 1-5
- AMMOM, Puerto Vallarta Jalisco, Mexico, March 17-20
- Osteologie, Erlangen, Germany, March 23-25
- **CO17 (ISCD/NOF Joint Congress), Orlando, USA, April 20-22, Booth #4**
- JPR, Sao Paulo, Brazil, May 4-7
- SSR/SS, Bern, Switzerland, June 8-10
- ANZBMS (ASM/JSBMR/IFMRS), Brisbane, Australia, June 17-21
- BRS, Bristol, UK, June 25-27

